about
Receptor tyrosine kinase-mediated angiogenesisAssociation of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.Lead Phytochemicals for Anticancer Drug DevelopmentProteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclearInsufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFALower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study.Cellular and vaccine therapeutic approaches for gliomasPyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.Pleomorphic liposarcoma: clinical observations and molecular variables.Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression.Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.Parent of origin influences the cardiac expression of vascular endothelial growth factor (Vegfa).High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival.Therapeutic potential of midkine in cardiovascular disease.Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.Novel targeted therapies in head and neck cancer.Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy.Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Design and evaluation of radiolabeled tracers for tumor imaging.Biomarkers in diabetic retinopathy and the therapeutic implications.Molecularly targeted therapies in multiple myelomaIntracameral bevacizumab administered for non-small cell lung cancer metastasis to iris.Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema.Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
P2860
Q27001612-766E2979-C483-44F7-9933-A0E95368B81AQ27852713-A9ABAF84-2E6E-457F-A422-B360F01BADCCQ28074591-D8157E99-5F29-460E-AE2B-078E45AD1F4BQ28482364-E0F5C451-6CFE-40E3-9BC7-D1E58899022DQ28483727-B44EFBE2-4896-4542-AB92-186F220CFBD7Q30831967-AACB8A46-9AE3-4FA9-B37E-41C2E88EC632Q31060162-E33D78FA-F334-4C46-A179-FF10DF231ECDQ33916673-2770A517-4BF5-4246-B7DA-D2F940C9EA9FQ34243550-FBDC732F-D954-425D-86C6-4CDC331C9D80Q35125613-CB74AF49-EE86-4DD3-9EB5-C100A12626E1Q35133246-ED724AA3-12C9-4EC4-98E9-544F18623FEDQ35179511-AFA6BB5F-A932-4A16-84AD-6BA593C9F938Q35705156-1BB51C61-621B-43E1-ADE7-3559DD306BEFQ36189375-9E400CB1-3F77-40AE-A969-C7B2330BB51BQ36395332-54F34D32-3C7D-48D5-93A0-64E9EC9CB693Q36526512-2F7267C5-9F38-41C7-B9EE-57BB0349E917Q36652690-4CEE5254-E197-4EE3-91D0-A5E1047EF993Q36766845-C5AFE385-8FC4-4D71-8A02-11B29F875D94Q36896177-B21FB7C3-8891-4F13-8586-AE90B52C64C0Q37585406-5EA610D6-DE78-4335-BCE0-E952C1DB508DQ37830361-E20FA6BE-90CB-429C-9145-2957EB76AE5EQ37852794-8ACE43AB-1FBE-462F-972E-5C8DFCC4861FQ37975224-F15EDC76-6473-48D2-AB68-54CC67E31C64Q38002923-E5D7B966-8B36-4E06-BCA8-2DFC4B244087Q38068203-EDD4FAA7-0EC2-4DCB-882D-9DA5600DF0E9Q38137253-EE350D6D-ABF6-4410-A6DF-8605B0D595C6Q38169142-D6382B60-2B1E-4F82-AC96-4CD99D50F42CQ38211866-C97850B9-9295-4140-B497-469FD94137D1Q38678960-F8B1B272-6546-4518-A798-9A56859FA88DQ41889215-7135ED0E-0B60-42DB-B958-C1547A41FC6CQ44361743-05B620E8-F554-468E-A07E-5159F2B7F4BAQ47322584-EC305BC5-1B7F-40BB-B536-DBB5B173B690Q51289585-3E761B07-20E6-4326-89A1-EF45F3EC064E
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Bevacizumab: current updates in treatment.
@en
Bevacizumab: current updates in treatment.
@nl
type
label
Bevacizumab: current updates in treatment.
@en
Bevacizumab: current updates in treatment.
@nl
prefLabel
Bevacizumab: current updates in treatment.
@en
Bevacizumab: current updates in treatment.
@nl
P1476
Bevacizumab: current updates in treatment.
@en
P2093
Edward S Kim
Margaret Em Van Meter
P304
P356
10.1097/CCO.0B013E32833EDC0C
P577
2010-11-01T00:00:00Z